ObjectiveTo explore the clinical effect of tiopronin combined with hepatocyte growth-promoting factor in the treatment of patients with chronic hepatitis B. MethodsA total of 90 patients with chronic hepatitis B who were admitted to our hospital from December 2017 to February 2020 were selected, and they were divided into observation group and control group by the random number method, with 45 cases in each group. Both groups were given conventional treatment, based on which the control group was additionally treated with tiopronin, whereas the observation group was additionally administrated with tiopronin and hepatocyte growth-promoting factor, for continuous treatment in 1 month. The pre- and post-treatment inflammatory response and liver and kidney function index levels were compared between the two groups. ResultsBefore treatment, there were no statistically significant differences in the levels of procalcitonin (PCT), C-reactive protein (CRP), endotoxin, urea nitrogen (BUN), cholinesterase (CHE), creatinine (Cr) and hepatitis B virus deoxyribonucleic acid (HBV DNA) between the two groups (P＞0.05). After 1 month of treatment, the levels of PCT, CRP, endotoxin, BUN, Cr, and HBV DNA in the observation group were significantly lower than those in the control group, whereas the CHE level was significantly higher than that in the control group, with statistically significant differences (P＜0.05). ConclusionOn the basis of conventional treatment, tiopronin combined with hepatocyte growth-promoting factor can significantly reduce the inflammatory response and improve liver and kidney function in patients with chronic hepatitis B, with a prominent clinical efficacy.

无